Drug-induced liver injury: insights from genetic studies.

Abstract:

:Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not reported. The general view is that idiosyncratic DILI, which is not predictable whether based on the pharmacology of the drug or on the dose administered, is determined by the presence in the recipient of variants in, or expression of, genes coding for key metabolic pathways and/or the immune response, and the interaction of these genetic variants with environmental variables. Furthermore, idiosyncratic DILI is an example of a complex-trait disease with two or more susceptibility loci, as reflected by the frequency of genetic variants in the population often being higher than the occurrence of significant liver injury. Polymorphisms of bioactivation/toxification pathways via the CYP450 enzymes (Phase I), detoxification reactions (Phase II) and excretion/transport (Phase III), together with immunological factors that might determine DILI are reviewed. Challenges such as gene-trait association studies and whole-genome studies, and future approaches to the study of DILI are explored. Better knowledge of the candidate genes involved could provide further insight for the prospective identification of susceptible patients at risk of developing drug-induced hepatotoxicity, development of new diagnostic tools and new treatment strategies with safer drugs.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Andrade RJ,Robles M,Ulzurrun E,Lucena MI

doi

10.2217/pgs.09.111

subject

Has Abstract

pub_date

2009-09-01 00:00:00

pages

1467-87

issue

9

eissn

1462-2416

issn

1744-8042

journal_volume

10

pub_type

杂志文章,评审
  • DEPTOR polymorphisms influence late complications in Type 2 diabetes patients.

    abstract::Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitu...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0058

    authors: Klen J,Goričar K,Horvat S,Stojan J,Dolžan V

    更新日期:2019-08-01 00:00:00

  • Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.

    abstract:AIMS:S-1, an oral fluoropyrimidine, contains tegafur, which is converted to 5-fluorouracil mainly by CYP2A6. We evaluated the association between CYP2A6 polymorphisms and treatment outcome in metastatic gastric cancer patients treated with S-1 plus docetaxel. MATERIALS & METHODS:Chemonaive patients received S-1 40 mg/...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.48

    authors: Kong SY,Lim HS,Nam BH,Kook MC,Kim YW,Ryu KW,Lee JH,Choi IJ,Lee JS,Park YI,Kim NK,Park SR

    更新日期:2009-07-01 00:00:00

  • miRNAs: from neurogeneration to neurodegeneration.

    abstract::miRNAs are reported to sequence-specifically control the translation of target mRNAs by binding to 3 UTRs. The abundant expression of miRNAs in the brain highlights their biological significance in neurodevelopment. Many studies have shown that miRNAs are involved in a variety of functions, including developmental tra...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.8.971

    authors: Singh SK

    更新日期:2007-08-01 00:00:00

  • Evaluation of a shared pharmacogenomics curriculum for pharmacy students.

    abstract:AIM:This national dissemination study evaluated pharmacy students' self-reported overall ability, self-efficacy and attitudes toward applying pharmacogenomics and perceptions of Pharmacogenomics Education Program, a shared pharmacogenomics curriculum. PATIENTS & METHODS:Following a series of train-the-trainer programs...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.181

    authors: Lee KC,Hudmon KS,Ma JD,Kuo GM

    更新日期:2015-01-01 00:00:00

  • Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.

    abstract:AIMS:To develop a novel warfarin-dosing algorithm based on a previous population pharmacokinetic/pharmacodynamic (PK/PD) model with Bayesian forecasting to facilitate warfarin therapy. MATERIALS & METHODS:Using information on CYP2C9 and VKORC1 genotypes, S-warfarin level, dose and international normalized ratio (INR) ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.65

    authors: Sasaki T,Tabuchi H,Higuchi S,Ieiri I

    更新日期:2009-08-01 00:00:00

  • A potential role for the CDH13/CDH15 gene in repeat revascularization after first percutaneous coronary intervention.

    abstract::Aim: Major drawbacks of percutaneous coronary intervention are the high occurrence of repeat revascularization due to restenosis and disease progression. The aim of this study was to find genetic indicators to predict the risk of repeat revascularization. Materials & methods: From April 2015 to June 2016, 143 patients...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0118

    authors: Xiang Q,Liu Z,Lu Y,Mao J,Chen S,Zhao X,Zhou S,Xie Q,Wang Z,Mu G,Jiang J,Gong Y,Cui Y

    更新日期:2020-01-01 00:00:00

  • Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.

    abstract:OBJECTIVES:In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.12.1705

    authors: Azuma M,Shi M,Danenberg KD,Gardner H,Barrett C,Jacques CJ,Sherod A,Iqbal S,El-Khoueiry A,Yang D,Zhang W,Danenberg PV,Lenz HJ

    更新日期:2007-12-01 00:00:00

  • Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients.

    abstract:AIM:This study aimed to investigate the effect of CYP3A4 and CYP3A5 genotypes on clinical outcomes of docetaxel treatment. PATIENTS & METHODS:In the PROMIX trial, 150 breast cancer patients received docetaxel preoperatively. CYP3A4 and CYP3A5 genotype combinations were transformed into total CYP 3A phenotypes. RESULT...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0080

    authors: Sim S,Bergh J,Hellström M,Hatschek T,Xie H

    更新日期:2018-11-01 00:00:00

  • SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis.

    abstract:AIM:Approximately a third of newly diagnosed epilepsy patients do not respond to antiepileptic drugs (AEDs). Evidence suggests that low penetrance variants in the genes of drug targets such as voltage-gated sodium channels may be involved in drug responsiveness. To examine this hypothesis, we compared data from two epi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析,多中心研究

    doi:10.2217/pgs.13.104

    authors: Haerian BS,Baum L,Kwan P,Tan HJ,Raymond AA,Mohamed Z

    更新日期:2013-07-01 00:00:00

  • Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology.

    abstract::The number of reports investigating disease susceptibility based on the carriage of low-penetrance, high-frequency polymorphisms has steadily increased over the last years. Evidence based on meta-analyses of individual case-control studies is accumulating, defining specific individual variations in disease susceptibil...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.5.1.57.25687

    authors: Tempfer CB,Schneeberger C,Huber JC

    更新日期:2004-01-01 00:00:00

  • Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.

    abstract::Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a ma...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2017-0055

    authors: Zuiverloon TC,Theodorescu D

    更新日期:2017-08-01 00:00:00

  • Race does not explain genetic heterogeneity in pharmacogenomic pathways.

    abstract:INTRODUCTION:Polymorphic alleles in the human genome have been identified as affecting numerous drug responses. Currently, genotyping of all patients before starting a drug regimen is impractical. Since many polymorphisms occur at varying rates in different racial groups, we investigated whether a patient's race could ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.11.1639

    authors: Yen-Revollo JL,Auman JT,McLeod HL

    更新日期:2008-11-01 00:00:00

  • Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.

    abstract:AIM:To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. METHODS:A comprehensive search was performed up to June 2013. The methodological quality of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.14.52

    authors: Cargnin S,Jommi C,Canonico PL,Genazzani AA,Terrazzino S

    更新日期:2014-05-01 00:00:00

  • Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

    abstract::Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the alle...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.10.1543

    authors: Ferrell PB Jr,McLeod HL

    更新日期:2008-10-01 00:00:00

  • The changing field of vaccine development in the genomics era.

    abstract::An improved understanding of the human immune system and the genetic make-up of pathogens, together with advances in instrumentation and bioinformatics, have provided new insights into the variation of immune responses to vaccines within the human population. Pathogen variation and the diversity of the immune system c...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.5.6.597

    authors: Brusic V,August JT

    更新日期:2004-09-01 00:00:00

  • Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer.

    abstract::Aim: To define the impact of polymorphisms in genes involved in platinum-taxane and estrogen activity in the outcome of platinum-based treated ovarian cancer patients (OCP). Patients & Methods: Two hundred and thirty OCP were analyzed for 124 germ-line polymorphisms to generate a prognostic score for overall survival ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0049

    authors: Gagno S,Bartoletti M,Romualdi C,Poletto E,Scalone S,Sorio R,Zanchetta M,De Mattia E,Roncato R,Cecchin E,Giorda G,Toffoli G

    更新日期:2020-09-01 00:00:00

  • Applications of biochip and microarray systems in pharmacogenomics.

    abstract::A DNA microarray system is usually comprised of DNA probes formatted on a microscale on a glass surface (chip), plus the instruments needed to handle samples (automated robotics), to read the reporter molecules (scanners) and analyse the data (bioinformatic tools). Biochips are formed by in situ (on chip) synthesis of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.1.3.289

    authors: Jain KK

    更新日期:2000-08-01 00:00:00

  • Applications of pharmacogenomics in general dental practice.

    abstract::The human oral cavity represents a complex ecology of approximately 500 microbial species existing as commensals, and interacting with human/host factors. Perturbation of this ecosystem can lead to diseases of the oral cavity. The oral cavity also acts as a mirror of complex systemic diseases. Unique challenges and op...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.4.2.163.22626

    authors: Slavkin HC

    更新日期:2003-03-01 00:00:00

  • Clinical consequences of ADRbeta2 polymorphisms.

    abstract::The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.3.349

    authors: Hawkins GA,Weiss ST,Bleecker ER

    更新日期:2008-03-01 00:00:00

  • Epigenetics of cancer progression.

    abstract::Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.2.215

    authors: Vucic EA,Brown CJ,Lam WL

    更新日期:2008-02-01 00:00:00

  • Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians.

    abstract:AIM:No definite factors predict blood pressure response to angiotensin-converting enzyme-inhibitors. The aim of this study was to test the association of gene polymorphisms of the renin-angiotensin-aldosterone system with essential hypertension and anthropometric variables, intermediate phenotypes and gene polymorphism...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,随机对照试验

    doi:10.2217/14622416.9.10.1419

    authors: Filigheddu F,Argiolas G,Bulla E,Troffa C,Bulla P,Fadda S,Zaninello R,Degortes S,Frau F,Pitzoi S,Glorioso N

    更新日期:2008-10-01 00:00:00

  • Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

    abstract:AIMS:The importance of polymorphisms in the dihydropyrimidine dehydrogenase gene (DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU)-based chemotherapy is still unclear. This study aims to assess the predictive value of DPYD variation with respect to previously described DPYD variants for 5-FU toxicit...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.28

    authors: Amstutz U,Farese S,Aebi S,Largiadèr CR

    更新日期:2009-06-01 00:00:00

  • The genetics of fibromyalgia syndrome.

    abstract::Fibromyalgia syndrome (FMS) is a common chronic widespread pain syndrome mainly affecting women. Although the etiology of FMS is not completely understood, varieties of neuroendocrine disturbances, as well as abnormalities of autonomic function, have been implicated in its pathogenesis. The exposure of a genetically p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.1.67

    authors: Buskila D,Sarzi-Puttini P,Ablin JN

    更新日期:2007-01-01 00:00:00

  • The impact of HER2 overexpression on the miRNA and circRNA transcriptomes in two breast cell lines and their vesicles.

    abstract::HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and ci...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0182

    authors: Galli de Amorim M,Branco G,Valieris R,Tarcitano E,Tojal da Silva I,Ferreira de Araújo L,Noronha Nunes D,Dias-Neto E

    更新日期:2019-05-01 00:00:00

  • Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment.

    abstract:AIM:The genetic origin of familial combined hyperlipidemia (FCH) is not well understood. We used microarray profiling of peripheral blood monocytes to search novel genes and pathways involved in FCH. METHODS:Fasting plasma for determination of lipid profiles, inflammatory molecules and adipokines was obtained and peri...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.8.1035

    authors: Llaverias G,Pou J,Ros E,Zambón D,Cofán M,Sánchez A,Vázquez-Carrera M,Sánchez RM,Laguna JC,Alegret M

    更新日期:2008-08-01 00:00:00

  • Discovery Partners International.

    abstract::Discovery Partners International (Nasdaq: DPII) is a leader in collaborative drug discovery. DPI's integrated discovery framework encompasses a broad spectrum of capabilities in chemistry, biology, informatics, computational modeling and synthesis automation. DPI's approach to drug discovery places a heavy emphasis on...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.3.1.145

    authors: Herd C

    更新日期:2002-01-01 00:00:00

  • Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics.

    abstract::Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.12.1809

    authors: Abdolmaleky HM,Zhou JR,Thiagalingam S,Smith CL

    更新日期:2008-12-01 00:00:00

  • Qualitative gene profiling: a novel tool in genomics and in pharmacogenomics that deciphers messenger RNA isoforms diversity.

    abstract::RNA splicing is a tightly regulated process. It is essential for gene expression and, therefore, intervenes in every biological phenomenon in mammals. RNA splicing regulation is cell type-specific in such a way that a cellular situation can be characterised by its repertoire of spliced events, the spliceome. Compariso...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.1.2.187

    authors: Schweighoffer F,Ait-Ikhlef A,Resink AL,Brinkman B,Melle-Milovanovic D,Laurent-Puig P,Kearsey J,Bracco L

    更新日期:2000-05-01 00:00:00

  • Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.

    abstract::The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for ab...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2217/pgs.09.125

    authors: van Schie RM,Wadelius MI,Kamali F,Daly AK,Manolopoulos VG,de Boer A,Barallon R,Verhoef TI,Kirchheiner J,Haschke-Becher E,Briz M,Rosendaal FR,Redekop WK,Pirmohamed M,Maitland van der Zee AH

    更新日期:2009-10-01 00:00:00

  • Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.

    abstract::Human cytochrome P450 (CYP)3A is a major P450 enzyme found in the liver and gastrointestinal tract. It plays an important role in the metabolism of a wide variety of drugs, some endogenous steroids and harmful environmental contaminants. It has been shown that CYP3A alleles encoding enzymes with little or no activity ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.6.7.731

    authors: Liu CH,Peck K,Huang JD,Lin MS,Wang CH,Hsu WP,Wang HW,Lee HL,Lai ML

    更新日期:2005-10-01 00:00:00